Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Keywords

Brief description/objective

A significant number of patients with non-Hodgkin lym-phoma (NHL) are not cured with available treatments and will eventually relapse. Those patients might not be able to tolerate more bone marrow toxicity, limiting their treatment options. Preclinical in vitro studies have demonstrated a synergism of venetoclax and copanlisib in different lym-phomas. This may represent a safe and effective therapy for patients who relapsed or did not respond to standard therapy.